Clinical Research Directory

Inclusion Criteria: * Men aged 18 years or older with mCRPC (histologically or cytologically confirmed adenocarcinoma of the prostate) * Progressive disease as defined by the Prostate Cancer Clinical Trials Working Group 3 (PCWG3) under previous treatment with taxane chemotherapy (unless medically unsuitable) and at least one second-generation androgen receptor pathway inhibitor (ARPI) * Adequate bone marrow, hepatic, and renal function * Eastern Cooperative Oncology Group performance status of 0-2; * A life expectancy of at least 6 months. * On Ga-68 PSMA PET/CT, a maximum standardised uptake value (SUVmax) of at least 20 in at least one metastasis and SUVmax of at least 10 in measurable soft tissue metastases. * Patient has provided written informed consent * PSA progression: minimum of 2 rising PSA values from baseline measurement with interval of ≥1 wk between each measurement * Soft-tissue progression: per RECIST 1.1 * Bone progression: ≥2 new lesions on bone scan * At least 3 wk interval since completion of surgery or radiotherapy before registration Exclusion Criteria: * Patients with discordant metastases defined as positive on 2-\[¹⁸F\]fluoro-2-deoxy-D-glucose (FDG) PET-CT with minimal uptake on Ga-68-PSMA PET-CT * Previous treatment with another radioisotope * Other malignancies within the previous 2 years before registration other than basal cell or squamous cell carcinomas of skin or other cancers that are unlikely to recur within 24 months * Concurrent illnesses that could jeopardise the ability of the patient to undergo the trial procedures. * Patient has symptomatic brain metastases or leptomeningeal metastases * Patient has symptomatic or impending cord compression unless appropriately treated beforehand and clinically stable for \>4 wk